Recent Updates
Recently added Catalysts

LY3185643

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: Sep 30, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment23

FDA Designations

No designations recorded

Clinical trial landscape

LY3185643 · 1 trial · 1 indication

Phase 1 1
NCT02951780A Study of LY3185643 and rGlucagon in Healthy ParticipantsHealthy
COMPLETED23 Analytics
PHASE1COMPLETED
A Study of LY3185643 and rGlucagon in Healthy Participants
Healthy
NCT0295178023
Unlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3185643 and rGlucagon
0 (pre-dose), 15, 30, 60, 120 and 180 minutes post-dose

Maximum observed plasma concentration (Cmax) was assessed for LY3185643 and rGlucagon.

Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3185643 and rGlucagon
0 (pre-dose), 15, 30, 60, 120 and 180 minutes post-dose

Area under the concentration versus time curve from zero to infinity (AUC0-inf) was assessed for LY3185643 and rGlucagon.

Pharmacodynamics (PD): Change From Baseline in Maximum Concentration (Cmax) of Blood Glucose of LY3185643 and rGlucagon
-5, 0 (pre-dose), 5, 10, 15, 22, 30, 45, 60, 75, 90, 105, 120, 150, 180 minutes post-dose

Cmax was assessed for LY3185643 and rGlucagon.

Pharmacodynamics (PD): Change From Baseline in Maximum Concentration (Cmax) of C-peptide of LY3185643 and rGlucagon
-5, 0 (predose), 5, 15, 30, 60 and 120 minutes post-dose

Cmax was assessed for C-peptide of LY3185643 and rGlucagon

Pharmacodynamics (PD): Change From Baseline in Area Under the Concentration Time Curve (AUC) of Blood Glucose of LY3185643 and rGlucagon
-5, 0 (pre-dose), 5, 10, 15, 22, 30, 45, 60, 75, 90, 105, 120, 150, 180 minutes post-dose

Area under the concentration versus time curve from time zero to 3 hours \[AUC (0-3)\] was assessed for LY3185643 and rGlucagon.

Pharmacodynamics (PD): Change From Baseline in Area Under the Concentration Time Curve (AUC) of C-Peptide of LY3185643 and rGlucagon
-5, 0 (pre-dose), 5, 15, 30, 60 and 120 minutes post-dose

Area under the concentration versus time curve from time zero to 3 hours \[AUC (0-3)\] was assessed for C-peptide of LY3185643 and rGlucagon.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY3185643EXPERIMENTALLY3185643 administered subcutaneous (SC)
rGlucagonEXPERIMENTALrGlucagon administered subcutaneous (SC)

Interventions

NameTypeDescription
LY3185643DRUGAdministered SC
rGlucagonDRUGAdministered SC
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Are overtly healthy as determined by medical history and physical examination * Body mass index of 18.0 to 30.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have participated, within the last 30 days, in a clinical trial involving an investigational product * Kno...

Countries:Singapore
Unlock Eligibility Criteria

Frequently asked questions about LY3185643

What is LY3185643?

LY3185643 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. It is not yet approved and remains in clinical trials.

What is LY3185643 used for?

LY3185643 is being studied for use in healthy participants. The completed Phase 1 trial evaluated the drug in this population to assess its effects. As an investigational drug, its potential therapeutic applications have not been established, and it is not approved for any medical condition.

Who makes LY3185643?

LY3185643 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational small molecule drug.

What phase is LY3185643 in?

LY3185643 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval and is still undergoing clinical evaluation.

What clinical trials is LY3185643 in?

LY3185643 has been studied in one clinical trial, identified as NCT02951780. This was a Phase 1, randomized, double-blind, controlled study titled 'A Study of LY3185643 and rGlucagon in Healthy Participants.' The trial was conducted in Singapore with 23 participants and has been completed.

Is LY3185643 the same as rGlucagon?

No, LY3185643 is not the same as rGlucagon. The clinical trial NCT02951780 studied LY3185643 in combination with rGlucagon, indicating they are distinct agents. LY3185643 is an investigational small molecule, while rGlucagon is a separate drug used in the study.